HARI SREENIVASAN: Another medical story that caught our attention this week. Word of what’s described as a pioneering clinical trial for patients with advanced lung cancer. What’s novel is not necessarily the drugs being used, but how many and how they’re being targeted. Dr. Mark Kris, an oncologist at Memorial Sloan Kettering Cancer Center, joins us. So what are they doing in the U.K. with this clinical trial? What’s so interesting about it? DR. MARK KRIS: They are taking a discovery that was made here almost ten years ago now where specific genes are damaged in lung tumors. And the...